In pancreatic cancer, multiple FAP‐targeted probes, such as TEFAPI‐06 and 07, as well as 177Lu–FAPI‐46, have demonstrated improved tumor retention and significant tumor growth inhibition in mouse models. Here, FAP is linked to neoplasm.